Gore Range Capital

Gore Range Capital is a venture capital firm dedicated to investing in early and growth-stage healthcare businesses, particularly those focused on skin health. The firm combines the operational focus of private equity with the guidance needed in venture capital, offering not just capital but also operational, clinical, and scientific expertise. Founded in 2015 and based in New York, Gore Range Capital leverages its team's extensive experience and deep industry relationships to support portfolio companies in bringing skin health innovations to market.

The firm's investment strategy centers on partnering with industry pioneers and working closely with portfolio companies to advance dermatological treatments and technologies. Gore Range Capital's team comprises experienced healthcare investors, leaders, and practitioners who provide strategic, financial, and scientific expertise. The firm has established a renowned scientific advisory board to bolster deal flow, evaluate opportunities, and advise on research, adding further depth to their capabilities.

Gore Range Capital's portfolio includes companies such as Palvella Therapeutics, Castle Biosciences, and Conversa Health. The firm has made 15 investments, with its most recent on December 13, 2024, when Palvella Therapeutics raised a new funding round. Gore Range Capital has raised two funds, with the latest being Gore Range Capital Fund II, announced on March 3, 2021. The firm is led by CEO Ethan Rigel, with partners including Humberto Antunes, Frank DeBernardis, John Friedman, and Ting-Pau Oei. The investment professionals are supported by a scientific advisory board that helps bolster deal flow, evaluate opportunities, and advise on research, adding further depth to their capabilities.